Progression, not initiation: a 40-year distinction the headlines miss
The single biggest claim that stops people from researching peptides isn't supported by the data the way the headline reads. Here's the distinction that matters.
The most common reason people walk away from peptide research is a single sentence they read once: "peptides cause c*ncer."
It's the headline of a fear that has shaped the conversation for two decades. And the research it points to is real. But the research and the headline are not saying the same thing.
The distinction that matters is between initiation and progression.
What "initiation" means
C*ncer initiation is the event that turns a healthy cell malignant. A mutation, a viral integration, a chemical adduct on DNA. Once the cell is malignant, the question of what makes a tumor grow faster or slower is a separate question.
In four decades of growth-factor research, peptides like growth hormone, IGF-1, and analogs of GHRH have not been shown to initiate c*ncer in healthy cells. There is no proposed mechanism in the literature for that. There is also no epidemiological signal in the long-term data on patients who took GH replacement at clinical doses.
What "progression" means
Once a malignancy already exists, growth-factor signaling can affect how fast it grows. This is well documented. IGF-1 signaling pathways are upregulated in many tumor types, and that upregulation correlates with proliferation. This is why screening for occult malignancy is standard of care before clinical GH therapy is started, and why patients with active c*ncer are excluded from the studies.
The clinical concern is real. The clinical concern is also narrow. It is a contraindication for known disease, not evidence of causation.
What the long-term data actually shows
The closest natural experiment we have is acromegaly. Acromegaly is a state of chronically elevated GH and IGF-1, often by an order of magnitude over the normal range, sustained over decades. If GH itself were a c*ncer initiator, untreated acromegaly should be a c*ncer-generating machine.
The literature on long-term acromegaly outcomes shows elevated rates of colon polyps and modestly elevated rates of certain malignancies, but the magnitude of the effect is not the magnitude one would expect from a true initiator. The signal is closer to what you'd expect from a growth-promotion effect on existing pre-malignant or early-malignant cells.
A separate body of literature on Laron-syndrome cohorts, where IGF-1 signaling is genetically suppressed for life, shows lower c*ncer incidence. This is the mirror image. It supports a progression-modulating role, not an initiation role.
What this means for research-context decisions
If you're sourcing peptides for research and you read "peptides cause c*ncer," you should know what you're reading. The claim as written is not supported by the evidence base. The narrower clinical claim, that growth-factor signaling can accelerate the progression of existing malignancy, is well supported and is the reason responsible clinical protocols exclude patients with active disease.
These are not the same claim. The headline collapses them. The research distinguishes them.
References
This note is a summary of mainstream review literature on growth-factor signaling and oncology, including reviews on the IGF-1 axis in tumor biology, long-term acromegaly outcome studies, and the Laron-syndrome cohort literature. We don't link individual studies because the conclusions here are reviewed widely; readers wanting primary sources can search PubMed for "IGF-1 cancer review" and "acromegaly cancer incidence" as starting points.